Tango Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 23, 2026, 6:36 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedTango Therapeutics (TNGX) Reports 82% ORR in 2L/3L Pancreatic Cancer With Vopimetostat plus Daraxonrasib, Plans Phase 3 for 1H 2027 and Cuts Workforce 14%
4Oct. 5, 2026, 5:36 p.m. ETView on SEC.gov
4Sept. 24, 2026, 7:41 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:01 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:40 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:13 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 11:05 a.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 8:23 a.m. ETView on SEC.gov
SCHEDULE 13GAug. 14, 2026, 2:12 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 12, 2026, 12:01 p.m. ETView on SEC.gov
8-KAug. 11, 2026, 5:13 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
424B5Aug. 11, 2026, 5:10 p.m. ETView on SEC.gov
8-KAug. 11, 2026, 7:20 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
10-QAug. 11, 2026, 7:12 a.m. ETView on SEC.gov
8-K/AAug. 7, 2026, 6:41 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
8-KAug. 6, 2026, 5:30 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
4Aug. 5, 2026, 4:01 p.m. ETView on SEC.gov